Seeing Is Believing
Currently out of the existing stock ratings of Vikram Purohit, 60 are a BUY (46.15%), 67 are a HOLD (51.54%), 3 are a SELL (2.31%).
Analyst Vikram Purohit, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 45.25% that have a potential upside of 46.02% achieved within 137 days.
Vikram Purohit’s has documented 327 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on HALO, Halozyme Therapeutics at 14-May-2025.
Analyst best performing recommendations are on ARQT (ARCUTIS BIOTHERAPEUTICS ).
The best stock recommendation documented was for ARQT (ARCUTIS BIOTHERAPEUTICS ) at 12/21/2023. The price target of $11 was fulfilled within 71 days with a profit of $8.4 (323.08%) receiving and performance score of 45.5.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$180
$74.84 (71.17%)
$180
13 days ago
(22-May-2025)
6/39 (15.38%)
$75.65 (72.50%)
108
Buy
$162
$56.84 (54.05%)
$160
29 days ago
(06-May-2025)
2/4 (50%)
$49.84 (44.44%)
181
Buy
$153
$47.84 (45.49%)
$153
2 months 3 days ago
(01-Apr-2025)
8/12 (66.67%)
$41.33 (37.01%)
98
Buy
$216
$110.84 (105.40%)
$212
2 months 8 days ago
(27-Mar-2025)
18/21 (85.71%)
$94.23 (77.38%)
229
Buy
$190
$84.84 (80.68%)
$115
3 months 8 days ago
(27-Feb-2025)
19/20 (95%)
$63.59 (50.30%)
356
Which stock is Vikram Purohit is most bullish on?
Which stock is Vikram Purohit is most reserved on?
What Year was the first public recommendation made by Vikram Purohit?